

References

I-288

1. Rytelo (imetelstat) for injection, for intravenous use [package insert]. Geron Corporation. Foster City, CA. Revised 06/2024.
2. Clinical Pharmacology™ Compendium. 2024. Tampa FL: Gold Standard, Inc. Imetelstat.
3. Micromedex DrugDex Compendium®. 2024. Imetelstat.
4. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: myelodysplastic syndromes. Version 2.2024. Accessed June 18, 2024.
5. Platzbecker U, Santini V, Fenaux P, et al. Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo controlled, phase 3 trial. *Lancet*. 2024; 403: 249-60.
6. Steensma DP, Fenaux P, Van Eygen K, et al. Imetelstat achieves meaningful and durable transfusion independence in high transfusion-burden patients with lower-risk myelodysplastic syndromes in a phase II study. *J Clin Oncol*. 2021; 39(1): 48-56.